scholarly journals Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care

2010 ◽  
Vol 13 (7) ◽  
pp. 903-908 ◽  
Author(s):  
Scott A. Irwin ◽  
Alana Iglewicz
Keyword(s):  
Hospice Care ◽  
Depression And Anxiety ◽  
Oral Ketamine ◽  
Treatment Of Depression ◽  
Rapid Treatment

scholarly journals Daily Oral Ketamine for the Treatment of Depression and Anxiety in Patients Receiving Hospice Care: A 28-Day Open-Label Proof-of-Concept Trial

2013 ◽  
Vol 16 (8) ◽  
pp. 958-965 ◽  
Author(s):  
Scott A. Irwin ◽  
Alana Iglewicz ◽  
Richard A. Nelesen ◽  
Jessica Y. Lo ◽  
Connie H. Carr ◽  
...  
Keyword(s):  
Hospice Care ◽  
Depression And Anxiety ◽  
Proof Of Concept ◽  
Open Label ◽  
Oral Ketamine ◽  
Treatment Of Depression

scholarly journals Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review

Life ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 1186
Author(s):  
Mateusz Kowalczyk ◽  
Edward Kowalczyk ◽  
Paweł Kwiatkowski ◽  
Łukasz Łopusiewicz ◽  
Monika Sienkiewicz ◽  
...  
Keyword(s):  
Antidepressant Effect ◽  
Depression Symptoms ◽  
Drug Resistant ◽  
Depression And Anxiety ◽  
Psychoactive Substances ◽  
Worldwide Population ◽  
Treatment Of Depression ◽  
Resistant Depression ◽  
Depressive Episodes ◽  
Rapid Treatment

The SARS-CoV-2 coronavirus epidemic has led to an increase in the number of people with depression. Symptoms related to the mental sphere (mainly depression and anxiety) may be experienced by one third of the worldwide population. This entails the need for the effective and rapid treatment of depressive episodes. An effective drug seems to be s-ketamine, which was accepted in March 2019 by the Food and Drug Administration (FDA) for the treatment of drug-resistant depression. This drug provides a quick antidepressant effect with maximum effectiveness achieved after 24 h. It also appears to reduce the occurrence of suicidal thoughts. However, research into undesirable effects, especially in groups of people susceptible to psychotic episodes or those who use alcohol or psychoactive substances, is necessary.

Gene–environment interactions in animal models of depression and anxiety

2019 ◽  
pp. 63-76
Author(s):  
Daniela Felice ◽  
Anand Gururajan ◽  
Olivia F O’Leary ◽  
John F Cryan
Keyword(s):  
Anxiety Disorders ◽  
Target Genes ◽  
Preclinical Studies ◽  
Depression And Anxiety ◽  
Complex Interactions ◽  
Gene Environment ◽  
Animal Models Of Depression ◽  
Treatment Of Depression ◽  
Candidate Target ◽  
The Individual

Depression and anxiety disorders cause the greatest global disability in terms of impact on the individual, family, and society at large. The etiology of these disorders is multifactorial and includes complex interactions between genetic and environmental risk factors. This chapter reviews preclinical studies assessing the importance of gene–environment (G×E) interaction. Specifically, we focus on G×E studies assessing the roles of the hypothalamic–pituitary–adrenal (HPA) axis, serotonergic system, GABAergic system, and brain-derived neurotrophic factor (BDNF) system. Finally, novel candidate target genes for the treatment of depression and anxiety disorders are considered.

Mood disorders and outcomes in lung cancer patients undergoing surgery: a brief summery

2020 ◽  
Author(s):  
Maria Salvina Signorelli ◽  
Teresa Surace ◽  
Marcello Migliore ◽  
Eugenio Aguglia
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Mood Disorders ◽  
Psychiatric Symptoms ◽  
Depression And Anxiety ◽  
Lung Cancer Patients ◽  
Patients With Cancer ◽  
Treatment Of Depression ◽  
The Impact

Cancer is a leading cause of death worldwide. Literature reports depression and anxiety are the most common psychiatric symptoms in cancer patients. Notably, lung cancer is associated with major depressive disorder in 5–13% of cases. The present article aims to give an overview regarding the impact of mood disorders on the outcomes of patients affected by lung cancer. Our review showed that pharmacological treatment and psychotherapy can be useful to improve the quality of life of patients with lung cancer. Moreover, the treatment of depression and anxiety can be associated with a reduced mortality. In conclusion, it is important to consider psychiatric care as important as other adjuvant oncologic therapies in patients with cancer.

Sign in / Sign up

Export Citation Format

Share Document